|ASH 2020 Meeting Highlights in Myeloproliferative Neoplasms |
CME, CPE, CNE
Ruben Mesa, MD; Aaron T. Gerds, MD; and John Mascarenhas, MD
|Release Date: April 05, 2021|
Expiration Date: April 05, 2022
Explore new data on MPN presented at the 2020 ASH Annual meeting. In this activity, experts will discuss long-term outcomes of the CONTINUATION-PV trial comparing ropegylated interferon versus hydroxyurea; phase 2 study results of idasanutlin as second-line therapy; the efficacy of PTG-300 for anemia; results from the SIMPLIFY-2 study of momelotinib; data on CPI-0610; outcomes of imetelstat in high-risk patients; navitoclax in relapsed/refractory myelofibrosis; and the potential utility of the LSD1 inhibitor bomedemstat (IMG-7289).
This activity was previously presented as a live webinar with Q&A on March 08, 2021. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
|Begin, Earn CreditView Only, No Credit|